What it's for (Indications)
- Procaterol is indicated for the symptomatic treatment and prophylaxis of bronchospasm associated with reversible obstructive airway diseases.
- This includes conditions such as bronchial asthma, chronic bronchitis, and pulmonary emphysema.
- Its primary role is to provide long-acting bronchodilation, thereby alleviating symptoms like wheezing, shortness of breath, and chest tightness.
- It is also utilized in the prevention of exercise-induced bronchospasm.
- It is crucial to understand that procaterol, as a long-acting beta-2 adrenergic agonist (LABA), is intended for regular maintenance treatment and not for the relief of acute bronchospasm.
- For asthma, it is typically used in conjunction with an inhaled corticosteroid (ICS) to manage inflammation and ensure comprehensive disease control, as monotherapy with LABAs in asthma carries significant risks.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of procaterol must be individualized based on the patient's age, severity of the condition, and response to treatment. For adult patients, the typical oral dosage is 50 micrograms (µg) administered once or twice daily, usually in the morning and at bedtime, or as prescribed by a physician. In pediatric patients, the dosage is generally adjusted based on body weight or age, often using a syrup formulation, for example, 25 µg once or twice daily for children over 6 years of age, and smaller doses for younger children, always under strict medical supervision. When administered via inhalation, the dosage typically involves 10-30 µg once or twice daily. It is imperative that patients do not exceed the prescribed dose, as higher doses do not necessarily confer additional benefit but may increase the risk of adverse effects. Consistency in administration is key for optimal therapeutic outcomes. |
Safety & Warnings
Common Side Effects
- Common side effects associated with procaterol, consistent with its class as a beta-2 adrenergic agonist, primarily include transient cardiovascular and central nervous system effects.
- Patients may experience tremors, headaches, palpitations, and tachycardia.
- Other frequently reported adverse reactions include dizziness, nausea, muscle cramps, and insomnia.
- Less common but potentially serious side effects can involve cardiac arrhythmias, hypertension, hypokalemia, and hyperglycemia.
- Rarely, paradoxical bronchospasm, an acute and life-threatening worsening of breathing, may occur.
- Patients should be advised to seek immediate medical attention if they experience severe chest pain, irregular heartbeat, difficulty breathing, or any other concerning symptoms.
- The incidence and severity of these side effects may be dose-dependent and can vary among individuals.
Serious Warnings
- Black Box Warning: WARNING: ASTHMA-RELATED DEATH. Long-acting beta-2 adrenergic agonists (LABAs), such as procaterol, increase the risk of asthma-related death. Data from a large, placebo-controlled US study demonstrated an increase in asthma-related deaths in patients receiving another LABA. This finding is considered a class effect of LABAs. Procaterol, as a LABA, is not indicated for the primary treatment of asthma; it should only be used as concomitant therapy with an inhaled corticosteroid (ICS) for the treatment of asthma. LABAs should not be used as monotherapy for asthma. The safety and effectiveness of LABAs when used alone in asthma have not been adequately established. Procaterol is not to be used for the relief of acute symptoms of asthma or acute exacerbations of chronic obstructive pulmonary disease (COPD); an appropriate short-acting beta-agonist (SABA) should be used for this purpose. When asthma is well-controlled, consideration should be given to discontinuing procaterol if possible, and the patient should be maintained on ICS alone. Regular re-evaluation of treatment is necessary to ensure the lowest effective dose and duration of therapy.
- Procaterol should be used with extreme caution in patients with cardiovascular disorders, including coronary insufficiency, cardiac arrhythmias, and hypertension, as beta-agonists can exacerbate these conditions.
- Patients with diabetes mellitus should be closely monitored, as procaterol may cause transient hyperglycemia.
- Hypokalemia, sometimes severe, has been reported with beta-2 agonist therapy, and caution is advised in patients predisposed to low potassium levels or those on concurrent medications that may potentiate hypokalemia.
- Procaterol is not intended for the relief of acute asthma symptoms or acute exacerbations of COPD; an appropriate short-acting beta-agonist (SABA) should be prescribed for rescue therapy.
- It should not be initiated in patients during rapidly deteriorating asthma or COPD.
- Discontinuation should be considered if the patient's condition worsens despite treatment.
- Pregnancy and lactation require careful consideration, with benefits weighed against potential risks to the fetus or infant.
- Concurrent use with other sympathomimetic agents should be avoided due to the potential for additive adverse effects.
- The safety and efficacy in children younger than 6 years of age have not been fully established.
How it Works (Mechanism of Action)
Procaterol is a potent and selective long-acting beta-2 adrenergic receptor agonist. Its therapeutic action is primarily mediated through the stimulation of beta-2 adrenergic receptors located on the smooth muscle cells of the bronchi. Upon binding to these receptors, procaterol activates adenyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). The increased intracellular levels of cAMP lead to the activation of protein kinase A, which, in turn, phosphorylates various proteins involved in the regulation of smooth muscle tone. This cascade ultimately results in the relaxation of bronchial smooth muscle, leading to bronchodilation and an increase in airflow. Additionally, procaterol may exert other beneficial effects, such as inhibiting the release of inflammatory mediators from mast cells and reducing microvascular leakage in the airways. Its long duration of action is attributed to its chemical structure, which allows for sustained binding to the beta-2 receptor.